Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide maintenance in first-line treated mantle cell lymphoma (non-transplant candidates)
2008-006177-32Phase 3Terminated
- Sponsor
- Celgene Corporation
- Start
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in mantle cell lymphoma (MCL) comparing Lenalidomide maintenance with Placebo maintenance (2 arms). Primary endpoint: Progression-free survival. Started Oct 2009; status: terminated.
02
Drugs
lenalidomide
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2008-006177-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006177-32.